Endo, Inc. announced the launch of tiopronin delayed-release tablets, a generic version of Travere Therapeutics' THIOLA EC®.
"We're proud to provide high-quality, affordable choices to healthcare providers and their appropriate patients," said Scott Sims, Senior Vice President and General Manager, Endo Injectable Solutions & Generics. "The launch of tiopronin delayed-release tablets strengthens our generic product portfolio and underscores our reputation as a reliable supplier."
The medication is used in combination with high fluid intake, alkali (low acid), and dietary changes to help prevent the formation of one type (cystine) of kidney stones in certain adult and pediatric patients.
THIOLA EC® is a registered trademark of Mission Pharmacal Company.